| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO
1 company
Kenneth Allen Myszkowski last filed a Form 4 in January 2025, as Chief Financial Officer at ARWR. Kenneth Allen Myszkowski's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Kenneth Allen Myszkowski's trades have earned a middling insider score of 68/100 across 7 rated trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of -2.3%.
At the last filing, the largest reported position was 455,433 shares of ARWR. The ARWR filings lean toward selling, a net 669,053 shares.
Kenneth Allen Myszkowski has 36 Form 4 filings on record from March 2015 to January 2025, all as Chief Financial Officer at Arrowhead Pharmaceuticals (ARWR), 2015–2025.
The 84 reported transactions were 46 open-market sales, 21 option exercises, 11 stock awards and 4 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $23.5M.
The largest open-market sale was 43,505 shares of ARWR at an average $69.37 on November 9, 2020, about $3.0M.
2 of the 4 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell10b5-1 | 45,167 | $19.77 | $893,095.40 | -9.0% | -47.9% | +234.0% | |
| Mar 6, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 40,000 | $35.19 | $1,407,600.00 | -9.1% | -28.6% | -50.1% | |
| Jan 5, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell10b5-1 | 16,104 | $35.27 | $567,909.60 | -3.5% | -26.7% | -44.4% | |
| Jun 27, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 15,000 | $36.20 | $543,000.00 | -3.8% | -26.1% | -27.2% | |
| Dec 29, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 30,625 | $40.00 | $1,225,000.00 | -8.3% | -38.3% | -23.7% | |
| Jan 5, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 40,000 | $61.70 | $2,467,940.96 | -7.9% | -19.6% | -38.4% | |
| Jan 12, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 13,038 | $81.02 | $1,056,309.94 | -2.9% | - | - | |
| Jan 6, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sell | 30,625 | $72.44 | $2,218,477.01 | -6.3% | - | - | |
| Nov 9, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 43,505 | $69.37 | $3,018,070.50 | -9.2% | - | - | |
| Oct 20, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Chief Financial Officer | Sale+OE | 29,166 | $54.04 | $1,576,130.64 | -6.4% | - | - |